Sophiris Bio said Friday that it has raised approximately $5M, via a private placement from an investor. The publicly held firm, which trades as SPHS on the NASDAQ,"> Sophiris Bio said Friday that it has raised approximately $5M, via a private placement from an investor. The publicly held firm, which trades as SPHS on the NASDAQ,"> Sophiris Bio said Friday that it has raised approximately $5M, via a private placement from an investor. The publicly held firm, which trades as SPHS on the NASDAQ,">

TOP NEWS

Sophiris Bio Raises $5M Via PIPE

San Diego-based biopharmaceuticals firm b>a href="http://www.sophirisbio.com">Sophiris Bio said Friday that it has raised approximately $5M, via a private placement from an investor. The publicly held firm, which trades as SPHS on the NASDAQ, said the new investor paid $1.40 per share in the investment, and als will receive a warrant to purchase one-half of a share of the company's common stock at the same prive, five years from closing. Roth Capital was the placement agent on the fundraising. Sophiris is targeting treatments for prostate cancer, and is in Phase 2 development.